Physician profile
Mark L Messmer
NPI 1508209073
$8,133.55
in general payments reported to CMS, 2019-2025
15 companies · $350 in 2025
The $350 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,424 · 2023: $1,618 · 2024: $4,742 · 2025: $350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,698 · Food and Beverage: $2,012.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,697.86 |
| Food and Beverage | $2,011.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Microport Orthopedics INC | $4,100.06 | 2024 | Mpo Medial Pivot Knee |
| Tricoast Surgical Solutions LLC | $1,476.41 | 2022-2025 | |
| Si-Bone, INC. | $1,315.26 | 2022-2024 | |
| Stryker Corporation | $662.26 | 2022-2025 | Mako, Triathlon, Tornier Perform Anatomic Augmented Glenoid |
| Linkbio Corp | $271.38 | 2024 | |
| Amgen INC. | $90.15 | 2023-2025 | Krystexxa, Prolia, Evenity |
| Kowa Pharmaceuticals America, INC. | $46.50 | 2023 | Seglentis |
| Horizon Therapeutics Plc | $44.15 | 2023 | Krystexxa |
| Endo USA, INC. | $41.64 | 2024 | Xiaflex |
| Novo Nordisk INC | $16.98 | 2024 | Wegovy |
| Trice Medical, INC. | $16.88 | 2024 | |
| Fidia Pharma USA INC. | $15.12 | 2023 | Hymovis, Triluron |
| Medtronic, INC. | $14.34 | 2024 | Intellis Adaptivestim |
| Breg, INC | $12.24 | 2022 | |
| Heraeus Medical, LLC. | $10.18 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Messmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.